Switching From or To Vyleesi (Bremelanotide): Protocols, Timelines, and Clinical Guidance

How Bremelanotide Works: The Melanocortin Pathway

Bremelanotide is a synthetic cyclic peptide that binds melanocortin-4 receptors (MC4Rs) in the central nervous system, activating neural circuits involved in sexual arousal and desire. This is not the same pathway that flibanserin targets. The distinction matters for switching.

MC4Rs are expressed in the medial preoptic area and paraventricular nucleus of the hypothalamus, regions that integrate hormonal signals with motivated behavior 1. When bremelanotide binds these receptors, it triggers downstream signaling through oxytocin and dopamine pathways. The drug does not alter serotonin neurotransmission, which is the primary mechanism of flibanserin.

Because bremelanotide's half-life is approximately 2.7 hours, its pharmacologic activity is confined to a narrow window around dosing 2. No drug accumulates between uses. This on-demand pharmacokinetic profile is one of the core reasons switching to or from bremelanotide is simpler than switching between two daily medications. The drug reaches peak plasma concentration within approximately 1 hour of subcutaneous injection, and its effects on desire and arousal have been measured to persist for about 24 hours in some patients, based on daily diary data from the RECONNECT program 1.

When Switching Makes Clinical Sense

A switch is warranted when the current HSDD treatment produces insufficient benefit, intolerable side effects, or conflicts with the patient's lifestyle. Not every nonresponder to one drug will fail the other.

The two FDA-approved options for premenopausal hypoactive sexual desire disorder have markedly different tolerability profiles. In the RECONNECT Phase III trials (N=1,247), 40% of bremelanotide-treated patients reported nausea, though the rate dropped with repeated dosing 1. By contrast, flibanserin's most common adverse effects are dizziness (11.4%), somnolence (11.2%), and nausea (10.4%), as demonstrated in the SPROUT trial (N=1,187) 3. The flibanserin label carries a boxed warning about severe hypotension and syncope when combined with alcohol, a restriction enforced through the Addyi REMS program 4.

Common clinical scenarios that prompt a switch include:

• Flibanserin to bremelanotide: Patient reports daily pill fatigue, experiences persistent dizziness or somnolence, or wants to consume alcohol without restriction.
• Bremelanotide to flibanserin: Patient has strong needle aversion, experiences significant nausea with bremelanotide that does not attenuate, or prefers a continuous baseline effect rather than event-timed dosing.
• Either agent to off-label testosterone: Both approved drugs have failed to produce meaningful change in desire, or the patient has measurably low testosterone on laboratory evaluation.

Dr. Sheryl Kingsberg, who served as principal investigator for both the RECONNECT and SPROUT programs, has noted: "These two drugs are pharmacologically distinct enough that failure on one does not predict failure on the other. I routinely offer a trial switch before concluding that pharmacotherapy has failed" 5.

Switching From Flibanserin to Bremelanotide

No formal washout period is required. Bremelanotide can be used at the next anticipated sexual encounter after the last flibanserin dose, though allowing 3 to 5 days for full serotonergic clearance is a reasonable precaution.

Flibanserin's terminal half-life is approximately 11 hours, meaning the drug is effectively eliminated within 2 to 3 days of discontinuation 4. Because bremelanotide acts on melanocortin receptors rather than serotonin receptors, there is no pharmacodynamic overlap that would create an interaction risk. The FDA labeling for bremelanotide does not list flibanserin as a contraindication or precaution 2.

A practical switching protocol:

1. Stop flibanserin after the last evening dose.
2. No taper is needed. Flibanserin does not produce withdrawal symptoms or rebound effects in clinical trial data 3.
3. Administer the first bremelanotide 1.75 mg subcutaneous injection 45 minutes before the next desired sexual encounter. This can occur as early as the following day.
4. Pre-treat nausea if desired. The FDA label permits concomitant use of an antiemetic. Ondansetron 4 mg orally, taken 30 minutes before the bremelanotide injection, has been used in clinical practice 2.

Patients should be counseled that initial nausea rates are highest with the first few injections and tend to decrease over time. In RECONNECT, nausea leading to discontinuation occurred in only 7.3% of treated patients despite the 40% overall incidence rate, suggesting most patients found it manageable 1.

Switching From Bremelanotide to Flibanserin

Because bremelanotide is used on demand and clears within hours, the transition to daily flibanserin can begin immediately. Start flibanserin 100 mg at bedtime.

The key counseling point here is expectation management. Flibanserin does not produce an acute, event-timed effect the way bremelanotide does. Patients should not expect to feel a difference after the first dose. The SPROUT trial data showed that statistically significant separation from placebo in satisfying sexual events (SSEs) emerged at approximately 4 weeks, with the full effect observed at 8 weeks 3. In that trial, flibanserin produced a mean increase of 0.5 SSEs per month over placebo, a modest but statistically significant difference (P<0.001).

Before prescribing flibanserin, clinicians must enroll the patient in the Addyi REMS program and verify that the patient understands the alcohol interaction risk. Alcohol must be avoided for at least 2 hours after taking flibanserin and for at least 2 hours before the next dose the following evening 4. Moderate CYP3A4 inhibitors (fluconazole, erythromycin, certain oral contraceptives) also require dose adjustment or avoidance. This drug interaction profile is a common reason patients switch away from flibanserin in the first place.

A practical timeline:

1. Use the last bremelanotide injection as needed.
2. Begin flibanserin 100 mg at bedtime the same day or any day thereafter.
3. Avoid alcohol from the first flibanserin dose forward.
4. Assess response at 8 weeks. If no meaningful improvement in desire or SSEs, the Endocrine Society and ISSWSH guidelines recommend discontinuation 6.

Off-Label Switching Options: Testosterone and Beyond

When both FDA-approved agents fail, off-label transdermal testosterone at 300 mcg/day represents the most evidence-supported third-line option for premenopausal women with HSDD.

The 2019 Global Consensus Position Statement on Testosterone Therapy for Women, endorsed by the International Menopause Society and published in the Journal of Clinical Endocrinology and Metabolism, recommended testosterone therapy for postmenopausal women with HSDD after finding moderate-quality evidence of benefit 7. Data in premenopausal women are more limited, though several smaller trials have shown improvement in desire domain scores. No testosterone product is FDA-approved for women; prescribers typically use compounded formulations or fractional doses of male products.

Dr. Susan Davis, an endocrinologist at Monash University who led the global consensus effort, stated: "Testosterone therapy should not be given without a clinical diagnosis of HSDD. We do not support the use of testosterone for general well-being, cognitive enhancement, or musculoskeletal health in women" 7.

When transitioning from bremelanotide to testosterone:

• Bremelanotide can be stopped without taper. Its effects do not persist.
• Begin testosterone at 300 mcg/day transdermal (compounded cream or gel applied to the inner thigh or abdomen).
• Measure total and free testosterone at baseline and at 3 to 6 weeks to confirm physiologic levels (target: upper quartile of the premenopausal reference range) 7.
• Assess response at 12 weeks minimum. Testosterone's effects on desire take longer to manifest than either FDA-approved drug.

When transitioning from flibanserin to testosterone, stop flibanserin without taper and begin testosterone. No interaction is expected. Monitor lipids and hepatic function at baseline and 3 months, as recommended by the consensus statement 7.

What the RECONNECT Data Tell Us About Response Prediction

RECONNECT enrolled 1,247 premenopausal women with HSDD across two identically designed Phase III trials (Study 301 and Study 302). Bremelanotide 1.75 mg produced a statistically significant improvement over placebo in both co-primary endpoints: the Female Sexual Distress Scale, Desire/Arousal/Orgasm item (FSDS-DAO, change of -0.7 vs. placebo, P<0.001) and the Female Sexual Function Index desire domain (FSFI-d, change of +0.5 vs. placebo, P<0.001) 1.

A clinically important detail for switching decisions: response to bremelanotide varied by baseline distress severity. Patients with higher baseline FSDS-DAO scores tended to show larger absolute improvements, suggesting that women with greater distress burden may benefit more from this mechanism 8. This contrasts somewhat with flibanserin data, where baseline SSE count was a stronger predictor of absolute response.

For clinicians deciding between first-line bremelanotide or first-line flibanserin, the RECONNECT and SPROUT data do not directly compare the two agents. No head-to-head trial has been conducted. Treatment selection therefore relies on patient preference (daily pill versus on-demand injection), comorbidity profile (particularly alcohol use patterns and concomitant CYP3A4 inhibitor use), and insurance coverage.

Blood Pressure and Cardiovascular Monitoring During Switching

Bremelanotide produces transient increases in blood pressure. Systolic BP increased by a mean of 5 to 6 mmHg and diastolic BP by 3 to 4 mmHg in RECONNECT, peaking approximately 2 to 3 hours post-dose and resolving within 12 hours 2.

This effect has specific relevance for patients switching to bremelanotide. Women with uncontrolled hypertension (defined as systolic BP ≥160 mmHg or diastolic BP ≥100 mmHg on the FDA label) should not use bremelanotide. Those with controlled hypertension on antihypertensive therapy can use it but should monitor blood pressure during the first 1 to 2 doses 2. The cardiovascular contraindication was the most common reason for screening failure in the RECONNECT extension study, affecting approximately 3% of candidates 8.

Flibanserin does not raise blood pressure. It can cause hypotension, particularly when combined with alcohol. This means that patients switching from flibanserin to bremelanotide are moving from a hypotension risk to a hypertension risk. A baseline blood pressure check before the first bremelanotide injection is good clinical practice.

Dosing Limits and Frequency Caps

The FDA-approved bremelanotide dose is 1.75 mg subcutaneously, with a maximum of one injection per 24 hours and no more than 8 injections per month 2.

The 8-dose monthly cap exists not because of cumulative toxicity but because the RECONNECT program's median use was 4 to 5 doses per month, and safety data at higher frequencies were limited 1. For patients who find themselves consistently approaching the monthly cap, switching to daily flibanserin may be more appropriate, as it provides continuous coverage without dose-counting. Conversely, patients who have sexual encounters less than once per week may prefer the as-needed bremelanotide model over a daily pill they take 30 nights per month for activity that occurs 3 to 4 times.

The melanocortin-receptor pathway does not appear to develop tachyphylaxis. In the open-label extension of RECONNECT (up to 60 weeks of additional treatment), efficacy as measured by FSDS-DAO and FSFI desire scores was maintained without dose escalation 8. This finding supports the durability of bremelanotide response and argues against preemptive switching due to tolerance concerns.

Insurance, Cost, and Access Considerations

Bremelanotide carries a wholesale acquisition cost of approximately $950 for a carton of 8 single-use auto-injectors. Flibanserin is available as a generic (since 2022) at roughly $30 to $80 per month depending on pharmacy and insurance status 9. This cost differential affects switching decisions in practice, as many insurers require prior authorization for bremelanotide and may mandate a trial of flibanserin first.

The ISSWSH Clinical Practice Guidelines recommend that coverage decisions should not mandate sequential failure of one agent before allowing access to the other, since their mechanisms are distinct and patient-specific factors (not drug-class failure) should guide selection 6. Despite this position, most commercial formularies as of 2025 place bremelanotide on Tier 4 or higher.

Patients switching from bremelanotide to flibanserin for cost reasons should be counseled that the transition involves a 4- to 8-week onset period during which the acute, event-timed effect of bremelanotide will be lost before flibanserin reaches its full effect.